Merger Expected to Accelerate Development of Personalized Medicine Solutions
By HospiMedica International staff writers Posted on 28 Dec 2014 |
Acquisition of an American company specializing in data management and analysis by a worldwide leader in genomics research and diagnostics development is expected to decrease the complexity, time, and cost of genomic analysis and accelerate development of the science of personalized medicine.
The biotech company Roche (Basel, Switzerland), an acknowledged leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics, has announced the acquisition of the American company Bina Technologies, Inc. (Redwood City, CA, USA).
Bina’s integrated, scalable, and comprehensive analysis platform, Genomic Management Solution or Bina-GMS1, empowers clinical and academic researchers to gain insight from their genomics data sets by dramatically decreasing the complexity, time, and cost of the analysis, accelerating the science of personalized medicine. The Bina Genome Analysis Platform includes a cancer pipeline that implements an integrative approach to identify and rank the most clinically important mutations based on a combination of different algorithms, sequencing features, and prior knowledge.
"The acquisition of Bina is a significant step for Roche to enable the promise of personalized healthcare by delivering the highest quality genomic data possible," said Dan Zabrowski, head of sequencing at Roche. "Informatics and data management are critical to providing a seamless, end-to-end sequencing solution. Bina's products are designed to improve the efficiency and value of genomic analysis, and the company continues to develop new methodologies and algorithms that link NGS data to disease-relevant genetic markers."
"Roche's acquisition of Bina is a great validation of our work and technology. It is also an indication of how informatics and data science are going to play a major role in the future of medicine," said Narges Bani Asadi, CEO of Bina. "We found great alignment between our company's vision and values, and we are very excited about the possibilities of working with Roche's global team and serving academic, translational, and clinical research markets together in the future."
It is expected that the acquisition by Roche will enable Bina to accelerate product development and global commercialization of Bina-GMS as an enterprise software system supporting multiple sequencing technologies while developing a solution for Roche sequencing systems.
Related Links:
Roche
Bina Technologies, Inc.
The biotech company Roche (Basel, Switzerland), an acknowledged leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics, has announced the acquisition of the American company Bina Technologies, Inc. (Redwood City, CA, USA).
Bina’s integrated, scalable, and comprehensive analysis platform, Genomic Management Solution or Bina-GMS1, empowers clinical and academic researchers to gain insight from their genomics data sets by dramatically decreasing the complexity, time, and cost of the analysis, accelerating the science of personalized medicine. The Bina Genome Analysis Platform includes a cancer pipeline that implements an integrative approach to identify and rank the most clinically important mutations based on a combination of different algorithms, sequencing features, and prior knowledge.
"The acquisition of Bina is a significant step for Roche to enable the promise of personalized healthcare by delivering the highest quality genomic data possible," said Dan Zabrowski, head of sequencing at Roche. "Informatics and data management are critical to providing a seamless, end-to-end sequencing solution. Bina's products are designed to improve the efficiency and value of genomic analysis, and the company continues to develop new methodologies and algorithms that link NGS data to disease-relevant genetic markers."
"Roche's acquisition of Bina is a great validation of our work and technology. It is also an indication of how informatics and data science are going to play a major role in the future of medicine," said Narges Bani Asadi, CEO of Bina. "We found great alignment between our company's vision and values, and we are very excited about the possibilities of working with Roche's global team and serving academic, translational, and clinical research markets together in the future."
It is expected that the acquisition by Roche will enable Bina to accelerate product development and global commercialization of Bina-GMS as an enterprise software system supporting multiple sequencing technologies while developing a solution for Roche sequencing systems.
Related Links:
Roche
Bina Technologies, Inc.
Latest Business News
- Hologic Acquires Gynesonics to Strengthen Existing Gynecological Surgical Business
- Smith+Nephew and JointVue Partner on Ultrasound Preoperative Planning in Robotics-Assisted Surgery
- Stryker Completes Acquisition of NICO Corporation
- BD Completes Acquisition of Critical Care from Edwards Lifesciences
- ZOLL to Acquire Vyaire Medical’s Ventilator Business
- Getinge Acquires Organ Transport Products and Services Company Paragonix Technologies
- Stryker Acquires care.ai to Boost AI-Driven Healthcare
- Johnson & Johnson Acquires Cardiovascular Specialist V-Wave
- Abbott and Medtronic Global Partnership to Integrate Advanced Glucose Sensing Technology with Automated Insulin Delivery Systems
- Edwards Lifesciences Acquires Sheba Medical’s Innovalve Bio Medical
- International Hospital Federation Awards 2024 Finalists Announced
- 2024 World Medical Tourism Conference and Medical Tourism Expo to Showcase Latest Innovations
- BD Acquires Edwards Lifesciences' Critical Care Product Group for USD 4.2 Billion
- MEDICA INNOVATION FORUM for the Healthcare Innovations of the Future
- Johnson & Johnson Acquires Cardiovascular Medical Device Company Shockwave Medical
- Mindray to Acquire Chinese Medical Device Company APT Medical